Key Drivers
- Strong margins
- High leverage
- Robust FCF
AIAI Summary
Quest's pivot from a defensive, margin-driven lab operator to an AI- and diagnostics-led, M&A-driven growth story materially increases upside optionality but creates near-term margin and cash-flow risk due to heavy investments and leverage. Monitor quarterly operating cash flow cadence, visible deleveraging, and early commercial/payer traction for ctDNA/MRD or Quest AI Companion as the specific triggers to become bullish (PAMA cuts or continued OCF weakness would materially worsen the thesis).
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •High leverage
- •Robust FCF
DGX delivers strong margins, robust FY2025 free cash flow and solid returns on capital but is constrained by high leverage, tight liquidity and heavy intangibles.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Holding support
- •Failed reclaim
Over the last month the stock slipped from $202.41 to $195.26, showing a modest decline and short-term bearish bias while holding $194–$200 support but failing to reclaim $210–$212 resistance, so watch for a break below ~$194 for downside confirmation or a clear move above $210–$212 to re-establish an uptrend.
Rough ~7–8% drop from late-February highs indicating weakened momentum but not extreme oversold conditions
Sentiment & News
Key News Insights:
- •AI product launch
- •Leadership hires
- •Institutional inflows
Quest Diagnostics is doubling down on AI-driven, patient-facing digital tools (notably the Quest AI Companion) while beefing up M&A and board leadership amid mixed near-term market reaction and rising institutional ownership.
Strengthened AI focus and strategic hires improve long-term competitive positioning, but short-term share volatility likely continues until Q1 results and execution clarity
Similar Companies in Healthcare
Other companies in the same sector with AI ratings